Download PDF
CC BY-NC-ND 4.0 · AJP Rep 2018; 08(04): e335-e342
DOI: 10.1055/s-0038-1675832
Case Report
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Bromocriptine Use in Peripartum Cardiomyopathy: Review of Cases

Rebecca Simon
1   Irvine Department of Obstetrics and Gynecology, University of California, Orange, California
,
Sophia Yang
1   Irvine Department of Obstetrics and Gynecology, University of California, Orange, California
,
Afshan B. Hameed
1   Irvine Department of Obstetrics and Gynecology, University of California, Orange, California
› Author Affiliations
Further Information

Publication History

09 October 2017

12 September 2018

Publication Date:
21 November 2018 (online)

Also available at
   Permissions and Reprints

Abstract

Objective This study is to review published cases of peripartum cardiomyopathy (PPCM) treated with bromocriptine and outline pros and cons of the treatment strategy.

Data Sources Data were collected from PubMed/MedLine, ClinicalTrials.gov; the years 2007 to 2018 were searched for English-language articles. Search terms: “bromocriptine and peripartum cardiomyopathy”, “bromocriptine and cardiomyopathy.”

Methods of Study Selection This search strategy yielded 171 articles. After excluding duplicates, 86 studies were reviewed. Sixty-one articles involving the treatment of PPCMP were included, and of these, 17 were case reports of patients with PPCMP treated with bromocriptine; these studies were included in this review.

Tabulation, Integration, and Results Seventeen of these articles were case reports of patients with peripartum cardiomyopathy treated with bromocriptine that were included.

Conclusion Bromocriptine seems to be a promising treatment, there is currently insufficient evidence for universal utilization of bromocriptine for all patients with PPCMP. Addition of bromocriptine to the standard heart failure therapy should be individualized.

Keywords

peripartum cardiomyopthaty - bromocriptine - left ventricular function - recovery - pregnancy - right ventricular function

Précis

Bromocriptine seems to be a promising treatment for peripartum cardiomyopathy but there is a need for further clinical trials.


 

  • References

  • 1 Arany Z, Elkayam U. Peripartum cardiomyopathy. Circulation 2016; 133 (14) 1397-1409
    CrossrefPubMedSearch in Google Scholar
  • 2 Demakis JG, Rahimtoola SH. Peripartum cardiomyopathy. Circulation 1971; 44 (05) 964-968
    CrossrefPubMedSearch in Google Scholar
  • 3 Demakis JG, Rahimtoola SH, Sutton GC. , et al. Natural course of peripartum cardiomyopathy. Circulation 1971; 44 (06) 1053-1061
    CrossrefPubMedSearch in Google Scholar
  • 4 Sliwa K, Hilfiker-Kleiner D, Petrie MC. , et al; Heart Failure Association of the European Society of Cardiology Working Group on Peripartum Cardiomyopathy. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 2010; 12 (08) 767-778
    CrossrefPubMedSearch in Google Scholar
  • 5 Kolte D, Khera S, Aronow WS. , et al. Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States: a nationwide population-based study. J Am Heart Assoc 2014; 3 (03) e001056
    PubMedSearch in Google Scholar
  • 6 Brar SS, Khan SS, Sandhu GK. , et al. Incidence, mortality, and racial differences in peripartum cardiomyopathy. Am J Cardiol 2007; 100 (02) 302-304
    CrossrefPubMedSearch in Google Scholar
  • 7 Bouabdallaoui N, Mouquet F, Lebreton G, Demondion P, Le Jemtel TH, Ennezat PV. Current knowledge and recent development on management of peripartum cardiomyopathy. Eur Heart J Acute Cardiovasc Care 2017; 6 (04) 359-366
    CrossrefPubMedSearch in Google Scholar
  • 8 Hilfiker-Kleiner D, Sliwa K. Pathophysiology and epidemiology of peripartum cardiomyopathy. Nat Rev Cardiol 2014; 11 (06) 364-370
    CrossrefPubMedSearch in Google Scholar
  • 9 Desai D, Moodley J, Naidoo D. Peripartum cardiomyopathy: experiences at King Edward VIII Hospital, Durban, South Africa and a review of the literature. Trop Doct 1995; 25 (03) 118-123
    CrossrefPubMedSearch in Google Scholar
  • 10 Yancy CW, Jessup M, Bozkurt B. , et al; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2013; 62 (16) e147-e239
    CrossrefPubMedSearch in Google Scholar
  • 11 Yancy CW, Jessup M, Bozkurt B. , et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of America. J Am Coll Cardiol 2016; 68 (13) 1476-1488
    CrossrefPubMedSearch in Google Scholar
  • 12 Bollen IA, Van Deel ED, Kuster DW, Van Der Velden J. Peripartum cardiomyopathy and dilated cardiomyopathy: different at heart. Front Physiol 2015; 5: 531
    CrossrefPubMedSearch in Google Scholar
  • 13 Amos AM, Jaber WA, Russell SD. Improved outcomes in peripartum cardiomyopathy with contemporary. Am Heart J 2006; 152 (03) 509-513
    CrossrefPubMedSearch in Google Scholar
  • 14 Fett JD, Sannon H, Thélisma E, Sprunger T, Suresh V. Recovery from severe heart failure following peripartum cardiomyopathy. Int J Gynaecol Obstet 2009; 104 (02) 125-127
    CrossrefPubMedSearch in Google Scholar
  • 15 Elkayam U, Tummala PP, Rao K. , et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. N Engl J Med 2001; 344 (21) 1567-1571
    CrossrefPubMedSearch in Google Scholar
  • 16 Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy. Lancet 2006; 368 (9536): 687-693
    CrossrefPubMedSearch in Google Scholar
  • 17 Sliwa K, Förster O, Libhaber E. , et al. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J 2006; 27 (04) 441-446
    CrossrefPubMedSearch in Google Scholar
  • 18 Hilfiker-Kleiner D, Kaminski K, Podewski E. , et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 2007; 128 (03) 589-600
    CrossrefPubMedSearch in Google Scholar
  • 19 Forster O, Hilfiker-Kleiner D, Ansari AA. , et al. Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. Eur J Heart Fail 2008; 10 (09) 861-868
    CrossrefPubMedSearch in Google Scholar
  • 20 Rayburn WF. Clinical commentary: the bromocriptine (Parlodel) controversy and recommendations for lactation suppression. Am J Perinatol 1996; 13 (02) 69-71
    Thieme ConnectPubMedSearch in Google Scholar
  • 21 Bernard N, Jantzem H, Becker M. , et al; French Network of Regional Pharmacovigilance Centres. Severe adverse effects of bromocriptine in lactation inhibition: a pharmacovigilance survey. BJOG 2015; 122 (09) 1244-1251
    CrossrefPubMedSearch in Google Scholar
  • 22 Sliwa K, Blauwet L, Tibazarwa K. , et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation 2010; 121 (13) 1465-1473
    CrossrefPubMedSearch in Google Scholar
  • 23 Hilfiker-Kleiner D, Haghikia A, Berliner D. , et al. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. Eur Heart J 2017; 38 (35) 2671-2679
    CrossrefPubMedSearch in Google Scholar
  • 24 Haghikia A, Schwab J, Vogel-Claussen J. , et al. Bromocriptine treatment in patients with peripartum cardiomyopathy and right ventricular dysfunction. Clin Res Cardiol 2018
    PubMedSearch in Google Scholar
  • 25 Arrigo M, Blet A, Mebazaa A. Bromocriptine for the treatment of peripartum cardiomyopathy: welcome on BOARD. Eur Heart J 2017; 38 (35) 2680-2682
    CrossrefPubMedSearch in Google Scholar
  • 26 Hilfiker-Kleiner D, Meyer GP, Schieffer E. , et al. Recovery from postpartum cardiomyopathy in 2 patients by blocking prolactin release with bromocriptine. J Am Coll Cardiol 2007; 50 (24) 2354-2355
    CrossrefPubMedSearch in Google Scholar
  • 27 Habedank D, Kühnle Y, Elgeti T, Dudenhausen JW, Haverkamp W, Dietz R. Recovery from peripartum cardiomyopathy after treatment with bromocriptine. Eur J Heart Fail 2008; 10 (11) 1149-1151
    CrossrefPubMedSearch in Google Scholar
  • 28 Jahns BG, Stein W, Hilfiker-Kleiner D, Pieske B, Emons G. Peripartum cardiomyopathy--a new treatment option by inhibition of prolactin secretion. Am J Obstet Gynecol 2008; 199 (04) e5-e6
    PubMedSearch in Google Scholar
  • 29 Abe T, Amano I, Sawa R, Akira S, Nakai A, Takeshita T. Recovery from peripartum cardiomyopathy in a Japanese woman after administration of bromocriptine as a new treatment option. J Nippon Med Sch 2010; 77 (04) 226-230
    CrossrefPubMedSearch in Google Scholar
  • 30 Meyer GP, Labidi S, Podewski E, Sliwa K, Drexler H, Hilfiker-Kleiner D. Bromocriptine treatment associated with recovery from peripartum cardiomyopathy in siblings: two case reports. J Med Case Reports 2010; 4: 80
    CrossrefPubMedSearch in Google Scholar
  • 31 Emmert MY, Prêtre R, Ruschitzka F, Krähenmann F, Falk V, Wilhelm MJ. Peripartum cardiomyopathy with cardiogenic shock: recovery after prolactin inhibition and mechanical support. Ann Thorac Surg 2011; 91 (01) 274-276
    CrossrefPubMedSearch in Google Scholar
  • 32 Ballo P, Betti I, Mangialavori G, Chiodi L, Rapisardi G, Zuppiroli A. Peripartum cardiomyopathy presenting with predominant left ventricular diastolic dysfunction: efficacy of bromocriptine. Case Rep Med 2012; 2012: 476903
    PubMedSearch in Google Scholar
  • 33 Freerksen N, Jaekel J, Menon AK, Maass N, Bauerschlag D. Massive respiratory dysfunction as sign of fulminant peripartum cardiomyopathy (PPCM). Hypertens Pregnancy 2012; 31 (04) 451-453
    CrossrefPubMedSearch in Google Scholar
  • 34 Hilfiker-Kleiner D, Struman I, Hoch M, Podewski E, Sliwa K. 16-kDa prolactin and bromocriptine in postpartum cardiomyopathy. Curr Heart Fail Rep 2012; 9 (03) 174-182
    CrossrefPubMedSearch in Google Scholar
  • 35 Schroeter MR, Unsöld B, Holke K, Schillinger W. Pro-thrombotic condition in a woman with peripartum cardiomyopathy treated with bromocriptine and an Impella LP 2.5 heart pump. Clin Res Cardiol 2013; 102 (02) 155-157
    CrossrefPubMedSearch in Google Scholar
  • 36 Kotlica BK, Cetković A, Plesinac S, Macut D, Asanin M. Peripartum cardiomyopathy: a case of patient with triplet pregnancy. Clin Exp Obstet Gynecol 2016; 43 (02) 274-275
    PubMedSearch in Google Scholar
  • 37 Hamdan R, Nassar P, Zein A, Issa M, Mansour H, Saab M. Peripartum cardiomyopathy, place of drug therapy, assist devices, and outcome after left ventricular assistance. J Crit Care 2017; 37: 185-188
    CrossrefPubMedSearch in Google Scholar
  • 38 Horn P, Saeed D, Akhyari P, Hilfiker-Kleiner D, Kelm M, Westenfeld R. Complete recovery of fulminant peripartum cardiomyopathy on mechanical circulatory support combined with high-dose bromocriptine therapy. ESC Heart Fail 2017; 4 (04) 641-644
    PubMedSearch in Google Scholar
  • 39 Senanayake HM, Patabendige M. Two potentially lethal conditions of probable immune origin occurring in a pregnant woman: a case report. J Med Case Reports 2018; 12 (01) 158
    CrossrefPubMedSearch in Google Scholar
  • 40 Kryczka KE, Dzielińska Z, Franaszczyk M. , et al. Severe course of peripartum cardiomyopathy and subsequent recovery in a patient with a novel TTN gene-truncating mutation. Am J Case Rep 2018; 19: 820-824
    CrossrefPubMedSearch in Google Scholar
  • 41 Huang Y, Chen T, Zhang M, Yang X, Ding G, Yang L. Successful management of fatal peripartum cardiomyopathy in a young pregnant woman: a case report. Medicine (Baltimore) 2018; 97 (15) e0408
    PubMedSearch in Google Scholar